Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
Condition: Triple Negative Breast Cancer Interventions: Drug: epirubicin hydrochloride; Drug: Cyclophosphamide; Drug: Albumin bound paclitaxel; Drug: Toripalimab Sponsor: Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials